News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
335,179 Results
Type
Article (20184)
Company Profile (128)
Press Release (314867)
Multimedia
Podcasts (75)
Webinars (11)
Section
Business (105545)
Career Advice (882)
Deals (18559)
Drug Delivery (97)
Drug Development (50842)
Employer Resources (80)
FDA (7715)
Job Trends (7772)
News (186156)
Policy (17372)
Tag
Academia (738)
Accelerated approval (3)
Adcomms (17)
Allergies (46)
Alliances (27897)
ALS (59)
Alzheimer's disease (645)
Antibody-drug conjugate (ADC) (102)
Approvals (7725)
Artificial intelligence (153)
Autoimmune disease (17)
Automation (7)
Bankruptcy (177)
Best Places to Work (5564)
BIOSECURE Act (13)
Biosimilars (99)
Biotechnology (57)
Bladder cancer (41)
Brain cancer (19)
Breast cancer (117)
Cancer (1147)
Cardiovascular disease (118)
Career advice (716)
Career pathing (21)
CAR-T (56)
Cell therapy (159)
Cervical cancer (6)
Clinical research (42861)
Collaboration (501)
Compensation (191)
Complete response letters (23)
COVID-19 (1104)
CRISPR (27)
C-suite (166)
Cystic fibrosis (60)
Data (1268)
Decentralized trials (2)
Denatured (19)
Depression (27)
Diabetes (148)
Diagnostics (1823)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (22)
Drug discovery (82)
Drug pricing (120)
Drug shortages (30)
Duchenne muscular dystrophy (64)
Earnings (39461)
Editorial (34)
Employer branding (10)
Employer resources (74)
Events (48943)
Executive appointments (483)
FDA (8409)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (337)
Gene editing (54)
Generative AI (18)
Gene therapy (155)
GLP-1 (613)
Government (1872)
Grass and pollen (3)
Guidances (85)
Healthcare (5910)
Huntington's disease (14)
IgA nephropathy (22)
Immunology and inflammation (95)
Indications (19)
Infectious disease (1186)
Inflammatory bowel disease (90)
Inflation Reduction Act (9)
Influenza (25)
Intellectual property (59)
Interviews (116)
IPO (7392)
IRA (45)
Job creations (2439)
Job search strategy (649)
Kidney cancer (7)
Labor market (29)
Layoffs (290)
Leadership (16)
Legal (4123)
Liver cancer (32)
Lung cancer (171)
Lymphoma (94)
Machine learning (5)
Management (30)
Manufacturing (238)
MASH (55)
Medical device (1973)
Medtech (1976)
Mergers & acquisitions (11449)
Metabolic disorders (526)
Multiple sclerosis (51)
NASH (20)
Neurodegenerative disease (53)
Neuropsychiatric disorders (23)
Neuroscience (986)
NextGen: Class of 2025 (2361)
Non-profit (912)
Now hiring (23)
Obesity (329)
Opinion (193)
Ovarian cancer (35)
Pain (76)
Pancreatic cancer (42)
Parkinson's disease (89)
Partnered (11)
Patents (159)
Patient recruitment (51)
Peanut (16)
People (33603)
Pharmaceutical (74)
Pharmacy benefit managers (24)
Phase I (13442)
Phase II (18128)
Phase III (14555)
Pipeline (880)
Policy (134)
Postmarket research (1620)
Preclinical (4710)
Press Release (29)
Prostate cancer (66)
Psychedelics (16)
Radiopharmaceuticals (162)
Rare diseases (254)
Real estate (3178)
Recruiting (29)
Regulatory (12622)
Reports (23)
Research institute (822)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (64)
Series A (61)
Series B (37)
Service/supplier (7)
Sickle cell disease (37)
Special edition (16)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2015)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (55)
The Weekly (54)
Vaccines (289)
Venture capitalists (30)
Weight loss (249)
Women's health (14)
Worklife (8)
Date
Today (75)
Last 7 days (490)
Last 30 days (1630)
Last 365 days (16553)
2025 (6219)
2024 (17686)
2023 (19656)
2022 (25885)
2021 (26675)
2020 (24903)
2019 (20082)
2018 (15621)
2017 (17271)
2016 (16203)
2015 (18807)
2014 (14788)
2013 (12552)
2012 (13483)
2011 (13818)
2010 (12738)
Location
Africa (409)
Alabama (24)
Alaska (1)
Arizona (68)
Arkansas (8)
Asia (24987)
Australia (3235)
California (2781)
Canada (1180)
China (355)
Colorado (107)
Connecticut (106)
Delaware (83)
Europe (51674)
Florida (490)
Georgia (60)
Idaho (16)
Illinois (265)
India (20)
Indiana (182)
Iowa (3)
Japan (133)
Kansas (65)
Kentucky (18)
Louisiana (3)
Maine (4)
Maryland (393)
Massachusetts (2342)
Michigan (49)
Minnesota (146)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (11)
Nevada (19)
New Hampshire (8)
New Jersey (1114)
New Mexico (21)
New York (810)
North Carolina (532)
North Dakota (2)
Northern California (1190)
Ohio (84)
Oklahoma (5)
Oregon (22)
Pennsylvania (660)
Puerto Rico (12)
Rhode Island (18)
South America (609)
South Carolina (4)
Southern California (1134)
Tennessee (40)
Texas (367)
United States (11046)
Utah (60)
Virginia (94)
Washington D.C. (47)
Washington State (232)
Wisconsin (27)
335,179 Results for "kite pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Business
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
Cellares today announced that Kite , a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle.
June 27, 2024
·
2 min read
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Deals
M&A, IPOs Snarled by Policy Reality in Q1 as Pharmas Opt for Licensing Deals
M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.
May 7, 2025
·
3 min read
·
Annalee Armstrong
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Business
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL).
June 3, 2024
·
19 min read
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
1 of 33,518
Next
